Michael Kalb Net Worth

The estimated Net Worth of Michael Wayne Kalb is at least $3.04 Milione dollars as of 29 July 2022. Mr. Kalb owns over 47,767 units of Amarin Corp stock worth over $178,110 and over the last 5 years he sold AMRN stock worth over $0. In addition, he makes $2,858,230 as Chief Financial Officer, Senior Vice President e Assistant Secretary at Amarin Corp.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Kalb AMRN stock SEC Form 4 insiders trading

Michael has made over 28 trades of the Amarin Corp stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 47,767 units of AMRN stock worth $28,183 on 29 July 2022.

The largest trade he's ever made was exercising 120,000 units of Amarin Corp stock on 12 August 2021 worth over $282,000. On average, Michael trades about 22,080 units every 37 days since 2019. As of 29 July 2022 he still owns at least 301,882 units of Amarin Corp stock.

You can see the complete history of Mr. Kalb stock trades at the bottom of the page.

Michael Kalb biography

Michael Wayne Kalb serves as Chief Financial Officer, Senior Vice President, Assistant Secretary of the Company. Mr. Kalb served as Group Vice President, Chief Financial Officer and Chief Accounting Officer of Taro Pharmaceutical Industries Ltd. from August 2014 to June 2016. Prior to that, Mr. Kalb was GVP, Interim CFO and CAO from November 2010 to August 2014 and GVP, Chief Financial Officer—U.S. and CAO from May 2010 to November 2010. Mr. Kalb joined Taro in June 2009 as VP, Chief Financial Officer—U.S. He has over 20 years of financial and accounting advisory experience. From June 2004 to June 2009, Mr. Kalb served as a Director in the Accounting and Financial Consulting Group of Huron Consulting Group Inc. His experience also includes over ten years at Ernst & Young, LLP within the Transaction Advisory Services Group and Audit and Assurance Services Group. Mr. Kalb received a B.S. in Accounting from the University at Albany, State University of New York. Mr. Kalb is a Certified Public Accountant.

What is the salary of Michael Kalb?

As the Chief Financial Officer, Senior Vice President e Assistant Secretary of Amarin Corp, the total compensation of Michael Kalb at Amarin Corp is $2,858,230. There are 4 executives at Amarin Corp getting paid more, with John Thero having the highest compensation of $8,929,540.

How old is Michael Kalb?

Michael Kalb is 49, he's been the Chief Financial Officer, Senior Vice President e Assistant Secretary of Amarin Corp since 2016. There are 16 older and 1 younger executives at Amarin Corp. The oldest executive at Amarin Corp is Patrick O'Sullivan, 78, who is the Non-Executive Independent Director.

What's Michael Kalb's mailing address?

Michael's mailing address filed with the SEC is C/O AMARIN PHARMA, INC., 440 US HIGHWAY 22, BRIDGEWATER, NJ, 08807.

Insiders trading at Amarin Corp

Over the last 13 years, insiders at Amarin Corp have traded over $25,876,836 worth of Amarin Corp stock and bought 581,426 units worth $751,974 . The most active insiders traders include John F Thero, Steven B Ketchum e David M Stack. On average, Amarin Corp executives and independent directors trade stock every 10 days with the average trade being worth of $29,442. The most recent stock trade was executed by Aaron Berg on 2 August 2024, trading 160,000 units of AMRN stock currently worth $102,400.

What does Amarin Corp do?

amarin corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. amarin's product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. vascepa® (icosapent ethyl) is amarin's first fda approved product and is available in the united states by prescription. for more information about vascepa visit www.vascepa.com.

Complete history of Mr. Kalb stock trades at Amarin Corp

Amarin Corp executives and stock owners

Amarin Corp executives and other stock owners filed with the SEC include:

• John Thero,
  President, Chief Executive Officer, Director
• Stephen Ketchum,
  President - Research and Development, Senior Vice President, Chief Scientific Officer
• Joseph Kennedy,
  Executive Vice President, General Counsel, Secretary, Strategic Initiatives
• Aaron Berg,
  Senior Vice President, Chief Commercial Officer
• Michael Kalb,
  Chief Financial Officer, Senior Vice President, Assistant Secretary
• Joseph Zakrzewski,
  Non-Executive Independent Director
• Dr. Steven B. Ketchum Ph.D.,
  Pres of R&D, Exec. VP and Chief Scientific Officer
• Dr. Steven B. Ketchum,
  Pres of R&D, Sr. VP and Chief Scientific Officer
• Michael W. Kalb,
  CFO, Sr. VP & Assistant Sec.
• Aaron D. Berg,
  Exec. VP & Pres of U.S.
• Elisabeth Schwartz,
  IR Contact Officer
• Jan van Heek,
  Non-Executive Independent Director
• David Stack,
  Non-Executive Independent Director
• Kristine Peterson,
  Non-Executive Independent Director
• Patrick O'Sullivan,
  Non-Executive Independent Director
• Lars Ekman,
  Non-Executive Independent Chairman of the Board
• Alan J. Wills B.A., BA (Zoology), M.B.A., MBA,
  Exec. VP of Corp. Bus. Devel.
• Jason M. Marks J.D.,
  Chief Legal Officer & Corp. Sec.
• Karim Mikhail,
  Pres, CEO & Director
• Donna Pasek,
  Sr. VP of HR
• Rami Daoud,
  Sr. VP of Corp. Devel.
• Alina Kolomeyer,
  Director of Communications
• Daniel S. Dunham,
  Sr. VP & Chief Pharmaceutical Compliance Officer
• Healthcare Partners Ltd. Fo...,
  Director
• Louis Iii Sterling,
  
• Oliver O'connor,
  
• Paul Cohen,
  
• Kostas D Odysseas,
  
• Mark Di Paolo,
  
• Steven B Ketchum,
  Chief Scientific Officer
• Murray Stewart,
  
• Karim Mikhail,
  President and CEO
• Jason M. Marks,
  EVP,Chief Global Legal Officer
• Alfonso G Zulueta,
  
• Erin S. Enright,
  
• Thomas Charles Reilly,
  EVP and CFO
• Geraldine Murphy,
  
• Adam Mark Berger,
  
• Diane E. Sullivan,
  
• Olsen Per Wold,
  Director
• Keith Horn,
  
• Jonathan Provoost,
  EVP, Chief Legal Officer
• Patrice Eadon Bonfiglio,
  
• Patrick Holt,
  President and CEO